Mid-period crossings: the quarter's story is things that started during it and are still completing
The model's full reasoning — Q4 2022 call → NOThe question asks whether management's account of the reported period is built around real business activity that crossed from not-happening to happening partway through the period or just around its edges, and whether management makes clear that this newly started activity is still completing its climb, so the period's reported numbers averaged the 'before' and 'after' and therefore sit below the level at which the business is already running. Let me examine the transcript for evidence of: 1. Real business starts during or around the period, narrated as starts 2. The climb being incomplete, with reported numbers lagging the current run rate Looking at the transcript, the call covers fiscal 2022 (ended September 30, 2022). The main topics are: - Clinical trial progress (fazirsiran, ARO-APOC3, ARO-ANG3, ARO-C3, ARO-RAGE, ARO-MUC5AC, ARO-MMP7) - The Royalty Pharma deal (sold olpasiran royalties for $250M upfront) - this happened November 9, 2022, which is after the fiscal year end (September 30, 2022) - The "20 in '25" program - Financial results The Royalty Pharma deal closed on November 9, 2022, which is after the fiscal year ended September 30, 2022. Ken Myszkowski mentioned "Pro forma cash and investments at September 30, 2022 including the Royalty Pharma cash receipt would be $732.3 million." This is a pro forma figure, meaning the actual cash receipt came after the period end. However, the question is about "real business activity that crossed from not-happening to happening partway through the period" - meaning actual revenue-generating or operational activity, not financing transactions. Looking at the clinical programs: - ARO-MMP7: "In August, we filed a CTA to begin a Phase 1/2 clinical study" - this is a filing, not yet started dosing. James said "dosing in healthy volunteers should begin imminently" - so it hasn't started yet. - ARO-C3: "All of the SAD and MAD cohorts are fully enrolled" - this is ongoing, not a new start in the period. - ARO-RAGE and ARO-MUC5AC: "approaching full enrollment of the healthy volunteer SAD cohorts and are well into enrollment of the healthy volunteer MAD cohorts" - ongoing, not new starts. - Fazirsiran SEQUOIA: "The SEQUOIA data are mostly in now" - data collection completing, not a new start. The Royalty Pharma deal is a financing transaction, not business activity like shipping products or starting operations.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| AIN | Albany International Corp. | Q3 2023 | 2023-11-07 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| HLX | Helix Energy Solutions Group, Inc. | Q1 2018 | 2018-04-24 | B+ |
| SBSI | Southside Bancshares, Inc. | Q4 2017 | 2018-02-06 | A |
| ANIP | ANI Pharmaceuticals, Inc. | Q4 2016 | 2017-03-02 | B+ |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
AFL · Q2 2023 → YESThe question is about whether management's account of the just-reported period is built around real business activity that started partway through the period, and that the numbers average before and a...YES The transcript shows management's account centered on the Japan Post cancer insurance launch in early April, which began selling the product and drove a 60% sales increase as a major contributor. They describe the activity as real and transacting, with Dan Amos noting the significant contribution from the new product. Yoshizumi confirms gradual increase going forward, and Fred highlights runway for more agents and sales calming down after initial jump, indicating the Q2 numbers reflect partial ramp-up rather than full run-rate.
ESE · Q2 2016 → YESThe question is about whether management's account of the just-reported period is built around real business activity that started partway through the period, and that the numbers average before and a...YES The transcript shows management's account centered on the real mid-period start of Plastique's contribution (acquired partway through Q2, with two months of performance noted and "early performance consistent with our acquisition forecast"), treated as a key new segment. It also explicitly addresses the incomplete climb, noting that the reported Q 2 numbers lag due to partial contribution and that Q3/Q4 will see fuller periods plus seasonality, with the business already running at a higher level as the ramp continues.
PSX · Q4 2016 → YESThe question is about whether management's account of the just-reported period is built substantially around real business activity that crossed from not-happening to happening partway through the per...YES The transcript shows management centering the Q4 story on the Freeport LPG Export Terminal's real start: commissioning completed smoothly, first commercial cargo shipped mid-December (partial Q4 contribution), with full-quarter costs incurred but only partial revenue, and explicit ramp to near-capacity loading in January onward.